Clinical trial

Sequential Administration of FE75C and Docetaxel Versus Docetaxel/Cyclophosphamide in HER-2 Negative, Node Positive Breast Cancer

NCT01985724

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2007-10-01

PhasePHASE3

Study timeline

Study start (unknown)2007-10-01Date precision: month

Registry last updated2014-05-14

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Breast Cancerunresolved

Interventions

DocetaxelDRUG · verified · RxNorm: docetaxel

EpirubicinDRUG · verified · RxNorm: epirubicin

CyclophosphamideDRUG · verified · RxNorm: cyclophosphamide

5-fluoruracilDRUG

Granulocyte-colony stimulating growth factorDRUG

Sponsors & collaborators

Hellenic Oncology Research Grouplead sponsor

University Hospital of Cretecollaborator

Mapped research locations

AthensGreece5 ThessalonikiGreece1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT01985724 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.